Syntara’s Post

💡 HyBryte™: Advancing CTCL Care Soligenix (Nasdaq: SNGX) opens patient enrollment for its confirmatory trial of HyBryte™ for CTCL. ✅ Building on groundbreaking results to bring new hope to patients with limited options. 🔗 Read the full announcement: https://lnkd.in/esVpuvdH #CTCL #Biotech #BiotechNews #CancerResearch #FDA #FinancialNews #CapitalMarkets

Recent research from MST Access has reaffirmed Syntara's valuation at 𝐀$𝟎.𝟐𝟎/𝐬𝐡𝐚𝐫𝐞, suggesting a 𝟏𝟖𝟔% 𝐮𝐩𝐬𝐢𝐝𝐞 from the current price of A$0.07. Senior Analyst Chris Kallos noted, SNT-5505 demonstrates a unique and promising profile, showing sustained improvements in symptoms and spleen volume with no serious adverse events. Additional interim data expected in 1HCY25 with final results in 2HCY25 #Syntara #SNT #ASX #ASXNews #Biotech #Myelofibrosis #ClinicalTrials

We have a busy and productive period ahead with several key milestones approaching that have the potential to drive valuation in the next six months. Our myelofibrosis study is ongoing and nearly full recruited, with data expected later this year. We're also collaborating with Dr. Fiona Wood on a skin scarring study, with updates on recruitment and progress anticipated in the middle of 2024. These developments, along with the top-line data from our myelofibrosis trial expected in the latter part of the year, position Syntara for a period of potential growth. #Syntara #SNT #investors #clinicaltrials #myelofibrosis #biotech #biotechnology 

Watch now: Prescient Therapeutics’ CEO & MD Steven Yatomi-Clarke provides an update on our strategy and upcoming milestones 💡 https://hubs.ly/Q02qRymS0 Focusing on PTX-100, Steven discusses how the upcoming PTX-100 Phase 2 trials places the company at a major value inflection point. #Biotech #PTX100 #CellTherapies #CancerTherapies

PARTNERSHIP ANNOUNCEMENT: We’re thrilled to announce that Cellipont Bioservices has partnered with Xiogenix to bring the cutting-edge Ares™ X20 fill-and-finish system to our clients! This collaboration marks a significant step forward in enhancing the precision, efficiency, and safety of cell therapy manufacturing processes. Read the full press release here: https://lnkd.in/euEsFEVz #CellTherapy #GeneTherapy #CGT #Innovation #Biotech #CGTCDMO #AdvancedManufacturing #Partnerships #Collaboration

We’re excited to officially announce our partnership with Cellipont Bioservices, a leading cell therapy CDMO! Together, we’re bringing the cutting-edge Ares™ X20 fill-and-finish system to the forefront of cell therapy manufacturing, enhancing precision, efficiency, and quality.   This collaboration represents a shared commitment to innovation and excellence in biopharmaceutical technology. We’re thrilled to see how this partnership will advance the field and help deliver life-changing therapies to patients worldwide.   Read the full press release here: https://lnkd.in/euEsFEVz #Xiogenix #CellipontBioservices #ARESX20 #CellAndGeneTherapy #InnovationInBiotech #PartnershipForProgress  

#Singlecell Omics is a hot topic for #FOGBoston next week, and Scale Biosciences can't wait! Don't miss our talk at the Live Lounge on June 12, and be sure to join us at booth 10 to talk about #methylation, #RNAseq, #CRISPR, and more, brought to you, finally, at SCALE.

🚨 Missed Abbey Cutchin's talk, "Unlocking Single-Cell Multiomics and Morphology Analysis with #AVITI24 using Teton Chemistry"? No worries—we’ve got you covered! 🙌 Abbey will be at our booth, ready to chat in person. Here’s why you should stop by: ✨ Dive into the future of advanced sequencing and single-cell multiomics 🚀 Discover #Trinity™, simplified rapid workflow for targeted sequencing 🧬 Explore #AVITI24, our cutting-edge platform for integrated multiomics #elembio #sequencing #singlecell

🔹 BacterOMIC announces targets on a path to strategic deal   ◾ Learn more about follow-on objectives for the BacterOMIC project, responding to the identified expectations of potential acquirers. The project is thus entering the phase of building an optimal position from the point of view of conducting a strategic transaction.   Press release (EN) 👉 https://shorturl.at/a0IbM ◾ Interview with Scope Fluidics CEO, Piotr Garstecki (PL): 👉 https://shorturl.at/SXZgk #medtech #scopefluidics #bacteromic

Come hear our CEO and Co-founder Giuseppe Mazza at the Basic Science Retreat today at 5pm, where he’ll be sharing his journey from academia to the exciting world of biotech! Stick around afterwards for a roundtable discussion at 6pm, where he'll dive into the conversation with other experts in the field.   #Biotech #Academia #ECM #TheECMCompany #Engitix #Fibrosis #SolidTumours #BasicScienceRetreat2024